Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now

Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma

Status: Recruiting
Phase: Phase 2
Diagnosis: Brain/Neuro Cancer: Other Non-Glioblastoma
NCT ID: NCT01063114 (View complete trial on
DFCI Protocol ID: 09-361


There are two types of external radiation treatments (proton beam and photon beam). As part of the participant's treatment, they will receive radiation to the entire central nervous system (CNS); this is known as craniospinal irradiation (CSI). In the past, photon radiation therapy has been used for CSI. In this study we will be examining the effects of proton beam radiation therapy. Studies have suggested that this kind of radiation can cause less damage to normal tissue than photon radiation therapy. The physical characteristics of proton beam radiation let the doctor safely deliver the amount of radiation delivered to the tumor that is normally delivered through standard therapy but spare more normal tissue in the process.


Conducting Institutions:
Massachusetts General Hospital

Overall PI:
Torunn Yock, MD, Massachusetts General Hospital

Site-responsible Investigators:

Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - Participants must have undergone biopsy or attempted surgical resection and must have histologically confirmed medulloblastoma or pineoblastoma. - Participants may have had a gross total resection, sub-total resection or biopsy only. - For patients with prior chemotherapy, treatment must start within 35 days of definitive surgery or as indicated if enrolled on therapeutic study - Age range between 3 and 25 at the time of enrollment - Life expectancy of greater than 3 months - Blood laboratory values as outlined in the protocol - Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation Exclusion Criteria: - Patients with more than one previous chemotherapy regimen - Patients with recurrent disease - Patients with prior radiation therapy - Any major uncontrolled or poorly controlled intercurrent illness that would limit compliance with study requirements - Pregnant women
  •   Email
  •   Print
  •   Share
  • Make an Appointment

    • For adults:
      877-442-3324 (877-442-DFCI)

    • Quick access:
      Appointments as soon as the next day for new adult patients

    • For children:
      888-733-4662 (888-PEDI-ONC)

    • Make Appointment Online
dana farber logo

450 Brookline Avenue
Boston, MA 02215

Call us toll-free: 866-408-DFCI (3324)

Connect with us

Dana-Farber/Brigham and Women’s Cancer Center is ranked #4 nationally and the best in New England.


Dana-Farber/Boston Children's is ranked the #1 pediatric cancer center.

Sign-up for newsletters